title: Failure of in vitro-expanded hyperimmune cytotoxic T lymphocytes to affect survival of mouse embryos in vivo.
abstract: This study was designed to address the question; does expression of paternal histocompatibility antigens by fetal cells make them susceptible to immune attack in vivo during normal pregnancy? The experimental design was based on the rationale that, if alloantigens are presented by trophoblasts or other fetal cells in a manner which allows accessibility, in vitro-generated immune effector cells of combined helper/cytotoxic phenotype should produce fetal rejection of abortion. Similarly generated effector cells are capable of accelerating skin graft rejection and, when combined with IL-2 in vivo, are capable of causing regression of antigenic, but operationally non-immunogenic, tumors. The alloimmune effector cells generated in vitro during the current study were highly cytotoxic against normal adult target cells, whereas placental cells were completely resistant to cytolysis and fetal cells were only slightly susceptible. Adoptive transfer of effector cells to mice at different stages of gestation had no apparent effect on pregnancy outcome. In vivo administration of IL-2 and/or indomethacin, which expand effector cell numbers in vivo and block PGE2-mediated immune suppression, respectively, failed to potentiate the cellular effect. The data provide additional evidence that paternal histocompatibility antigens are not expressed in a format which allows susceptibility to immune attack during pregnancy. The data are discussed with respect to the role of the trophoblast in protecting developing embryos.
authors.affiliation: Department of Pathology and Oncology, University of Kansas Medical Center, Kansas City 66103.
authors.forename: S
authors.initials: S
authors.lastname: Kamel
authors.forename: G W
authors.initials: GW
authors.lastname: Wood
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004622:Embryo, Mammalian / Q000276:immunology*; D005260:Female; D005313:Fetal Death / Q000276:immunology; D006085:Graft Survival; D007108:Immune Tolerance; D016219:Immunotherapy, Adoptive; D007213:Indomethacin / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007519:Isoantigens / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D008809:Mice, Inbred C3H / Q000276:immunology; D009924:Organ Culture Techniques; D011247:Pregnancy; D011256:Pregnancy Outcome; D011994:Recombinant Proteins / Q000494:pharmacology; D016038:Skin Transplantation / Q000276:immunology; D016176:T-Lymphocyte Subsets; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014327:Trophoblasts / Q000276:immunology
chemical_list: D007376:Interleukin-2; D007519:Isoantigens; D011994:Recombinant Proteins; D007213:Indomethacin